id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0248-0006,FDA,FDA-2022-E-0248,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-05-27T04:00:00Z,2025,5,2025-05-27T04:00:00Z,,2025-05-27T22:17:54Z,,0,0,09000064863e62f8
FDA-2022-E-0248-0007,FDA,FDA-2022-E-0248,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-05-27T04:00:00Z,2025,5,2025-05-27T04:00:00Z,,2025-05-27T22:18:16Z,,0,0,09000064b8dc1645
FDA-2022-E-0248-0005,FDA,FDA-2022-E-0248,Letter from FDA CDER to U S Patent TradeMark Office,Other,Letter(s),2024-01-22T05:00:00Z,2024,1,2024-01-22T05:00:00Z,,2024-01-22T17:46:03Z,,0,0,09000064863ae2a4
FDA-2022-E-0248-0004,FDA,FDA-2022-E-0248,Determination of Regulatory Review Period for Purposes of Patent Extension; ZYNLONTA,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:00:21Z,2023-26982,0,0,0900006486316537
FDA-2022-E-0248-0003,FDA,FDA-2022-E-0248,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:43:52Z,,0,0,09000064852ceb12
FDA-2022-E-0248-0001,FDA,FDA-2022-E-0248,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T20:53:01Z,,0,0,0900006484fadffc
FDA-2022-E-0248-0002,FDA,FDA-2022-E-0248,Patent Extension Application from Casimir Jones S.C. (on behalf of ADC Therapeutics S.A. (ADCT),Other,Application,2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T20:53:05Z,,0,0,0900006484fae011